By Daniella Parra
Creyon Bio has added two prominent venture capitalists, Serge Messerlian from DCVC Bio and Shaquille Vayda from Lux Capital, to its Board of Directors, it said.
The company said Messerlian has a background in hematology, oncology, and rare diseases, while Vayda has experience in technology, aerospace, and life sciences, previously working at NASA and Illumina.
“We are excited to welcome Serge and Shaq officially to our Board of Directors, and their extensive experience in life sciences and technology aligns with Creyon’s mission to reimagine drug development through AI-enabled engineering of oligonucleotide-based medicines,” said Chris Hart, Ph.D., Co-Founder, Chief Executive Officer, and President of Creyon Bio. “Their insight and strategic guidance has been immensely valuable to date as observers and will be instrumental as Creyon advances best-in-class clinical assets created with its pioneering platform of oligonucleotide-based medicines.”
Contact:
Editor@executives-edge.com
